Multiplexed mAbs: A new strategy in preclinical time-domain imaging of acute myeloid leukemia

Blood

Volumn 121, Issue 7, 2013, Pages

  McCormack, Emmet ^a,b   Mujic, Maja ^a   Osdal, Tereza ^a,b   Bruserud, Oystein ^a,b   Gjertsen, Bjørn Tore ^a,b  

^a UNIVERSITY OF BERGEN   (Norway)

^b HAUKELAND UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; BIOLOGICAL MARKER; CD11B ANTIGEN; CYTARABINE; DAUNORUBICIN; FLUOROCHROME; GLYCOPROTEIN P 15095; GREEN FLUORESCENT PROTEIN; MONOCLONAL ANTIBODY; RETINOIC ACID; VALPROIC ACID;

ACUTE GRANULOCYTIC LEUKEMIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY LABELING; ARTICLE; AUTOFLUORESCENCE; BIOLUMINESCENCE; CONJUGATION; CONTROLLED STUDY; DIAGNOSTIC IMAGING; DRUG EFFICACY; HISTOPATHOLOGY; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; TIME DOMAIN IMAGING; TUMOR XENOGRAFT;

EID: 84874095141     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2012-05-429555     Document Type: Article

References (39)

1. Rollig C, Bornhauser M, Thiede C, et al. Long-term prognosis of acute myeloid leukemia according to the new genetic risk classification of the European Leukemia Net recommendations: evaluation of the proposed reporting system. J Clin Oncol. 2011;29(20):2758-2765.
2. Pollyea DA, Kohrt HE, Medeiros BC. Acute my-eloid leukaemia in the elderly: a review. Br J Haematol. 2011;152(5):524-542.
3. Burnett AK. New induction and postinduction strategies in acute myeloid leukemia. Curr Opin Hematol. 2012;19(2):76-81.
4. Burnett A, Wetzler M, Lowenberg B. Therapeutic advances in acute myeloid leukemia. J Clin Oncol. 2011;29(5):487-494.
5. McCormack E, Bruserud O, Gjertsen BT. Animal models of acute myelogenous leukaemia-development, application and future perspectives. Leukemia. 2005;19(5):687-706. (Pubitemid 40663086)
6. McCormack E, Bruserud O, Gjertsen BT. Review: genetic models of acute myeloid leukaemia. On-cogene. 2008;27(27):3765-3779. (Pubitemid 351862057)
7. Caponigro G, Sellers WR. Advances in the pre-clinical testing of cancer therapeutic hypotheses. Nat Rev Drug Discov. 2011;10(3):179-187.
8. Kerbel RS. Human tumor xenografts as predictive preclinical models for anticancer drug activity in humans: better than commonly perceived-but they can be improved. Cancer Biol Ther. 2003; 2(4 Suppl 1):S134-S139.
9. Peterson JK, Houghton PJ. Integrating pharmacology and in vivo cancer models in preclinical and clinical drug development. Eur J Cancer. 2004;40(6):837-844. (Pubitemid 38519762)
10. Pearce DJ, Taussig D, Zibara K, et al. AML en-graftment in the NOD/SCID assay reflects the outcome of AML: implications for our understanding of the heterogeneity of AML. Blood. 2006; 107(3):1166-1173. (Pubitemid 43156319)
11. Willmann JK, van Bruggen N, Dinkelborg LM, Gambhir SS. Molecular imaging in drug development. Nat Rev Drug Discov. 2008;7(7):591-607. (Pubitemid 351927724)
12. McCormack E, Micklem DR, Pindard LE, et al. In vivo optical imaging of acute myeloid leukemia by green fluorescent protein: time-domain auto-fluorescence decoupling, fluorophore quantification, and localization. Mol Imaging. 2007;6(3): 193-204. (Pubitemid 47152706)
13. McCormack E, Haaland I, Venas G, et al. Syner-gistic induction of p53 mediated apoptosis by val-proic acid and nutlin-3 in acute myeloid leukemia. Leukemia. 2012;26(5):910-917.
14. Modlich U, Schambach A, Brugman MH, et al. Leukemia induction after a single retroviral vector insertion in Evi1 or Prdm16. Leukemia. 2008; 22(8):1519-1528.
15. Baum C. Insertional mutagenesis in gene therapy and stem cell biology. Curr Opin Hematol. 2007; 14(4):337-342. (Pubitemid 46842807)
16. Olafsen T, Wu AM. Antibody vectors for imaging. Semin Nucl Med. 2010;40(3):167-181.
17. Matthews DC, Appelbaum FR, Eary JF, et al. Development of a marrow transplant regimen for acute leukemia using targeted hematopoietic irradiation delivered by 131I-labeled anti-CD45 antibody, combined with cyclophosphamide and total body irradiation. Blood. 1995;85(4):1122-1131.
18. Leblond F, Davis SC, Valdes PA, Pogue BW. Pre-clinical whole-body fluorescence imaging: Review of instruments, methods and applications. J Pho-tochem Photobiol B. 2010;98(1):77-94.
19. Hofmann M, McCormack E, Mujic M, et al. Increased plasma colloid osmotic pressure facilitates the uptake of therapeutic macromolecules in a xenograft tumor model. Neoplasia. 2009; 11(8):812-822.
20. Erikstein BS, McCormack E, Tronstad KJ, Schwede F, Berge R, Gjertsen BT. Protein kinase A activators and the pan-PPAR agonist tetrade-cylthioacetic acid elicit synergistic anti-leukaemic effects inAML through CREB. Leuk Res. 2010; 34(1):77-84.
21. Karlsen TV, McCormack E, Mujic M, Tenstad O, Wiig H. Minimally invasive quantification of lymph flow in mice and rats by imaging depot clearance of near-infrared albumin. Am J Physiol Heart Circ Physiol. 2012;302(2):H391-401.
22. Saito Y, Kitamura H, Hijikata A, et al. Identification of therapeutic targets for quiescent, chemotherapy-resistant human leukemia stem cells. Sci Transl Med. 2010;2(17):17ra9.
23. Bellos F, Mahlknecht U. Valproic acid and all-trans retinoic acid: meta-analysis of a palliative treatment regimen inAMLand MDS patients. Onkologie. 2008;31(11):629-633.
24. Glasow A, Prodromou N, Xu K, von Lindern M, Zelent A. Retinoids and myelomonocytic growth factors cooperatively activate RARA and induce human myeloid leukemia cell differentiation via MAP kinase pathways. Blood. 2005;105(1):341-349. (Pubitemid 40053102)
25. Kern W, Bacher U, Haferlach C, Schnittger S, Haferlach T. The role of multiparameter flow cy-tometry for disease monitoring in AML. Best Pract Res Clin Haematol. 2010;23(3):379-390.
26. Kornblau SM, Minden MD, Rosen DB, et al. Dynamic single-cell network profiles in acute my-elogenous leukemia are associated with patient response to standard induction therapy. Clin Cancer Res. 2010;16(14):3721-3733.
27. Irish JM, Hovland R, Krutzik PO, et al. Single cell profiling of potentiated phospho-protein networks in cancer cells. Cell. 2004;118(2):217-228. (Pubitemid 38962577)
28. Perik PJ, Lub-De Hooge MN, Gietema JA, et al. Indium-111-labeled trastuzumab scintigraphy in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer. J Clin Oncol. 2006;24(15):2276-2282. (Pubitemid 46630657)
29. Gmeiner Stopar T, Fettich J, Zver S, et al. 99mTc-labelled rituximab, a new non-Hodgkin's lymphoma imaging agent: first clinical experience. Nucl Med Commun. 2008;29(12):1059-1065.
30. Kaur S, Venktaraman G, Jain M, Senapati S, Garg PK, Batra SK. Recent trends in antibody-based oncologic imaging. Cancer Lett. 2012; 315(2):97-111.
31. Tung CH, Mahmood U, Bredow S, Weissleder R. In vivo imaging of proteolytic enzyme activity using a novel molecular reporter. Cancer Res. 2000;60(17):4953-4958.
32. Ogawa M, Regino CA, Choyke PL, Kobayashi H. In vivo target-specific activatable near-infrared optical labeling of humanized monoclonal antibodies. Mol Cancer Ther. 2009;8(1):232-239.
33. Jung KH, Choe YS, Paik JY, Lee KH. 99mTc-Hydrazinonicotinamide epidermal growth factor-polyethylene glycol-quantum dot imaging allows quantification of breast cancer epidermal growth factor receptor expression and monitors receptor downregulation in response to cetuximab therapy. J Nucl Med. 2011;52(9):1457-1464.
34. McCarthy JR, Bhaumik J, Karver MR, Sibel Erdem S, Weissleder R. Targeted nanoagents for the detection of cancers. Mol Oncol. 2010;4(6): 511-528.
35. Pesnel S, Pillon A, Creancier L, et al. Optical imaging of disseminated leukemia models in mice with near-infrared probe conjugated to a monoclonal antibody. PLoS One. 2012;7(1):e30690.
36. Buccisano F, Maurillo L, Del Principe MI, et al. Prognostic and therapeutic implications of minimal residual disease detection in acute myeloid leukemia. Blood. 2012;119(2):332-341.
37. Vanderhoek M, Juckett MB, Perlman SB, Nickles RJ, Jeraj R. Early assessment of treatment response in patients with AML using [(18)F]FLT PET imaging. Leuk Res. 2011;35(3): 310-316.
38. Buck AK, Bommer M, Juweid ME, et al. First demonstration of leukemia imaging with the proliferation marker 18F-fluorodeoxythymidine. J Nucl Med. 2008;49(11):1756-1762.
39. Buss EC, Ho AD. Leukemia stem cells. Int J Cancer. 2011;129(10):2328- 2336.